Mytonomy Pioneers Multicultural Diabetes Education with Sanofi and Preeminent Academic Partners
Bethesda, Maryland (PRWEB) September 08, 2017 -- Mytonomy today announced that it has worked over the last six months on modern, culturally relevant microlearning patient education for new insulin users in partnership with Sanofi. The collaboration marries Sanofi’s work in putting patients at the center of care delivery and research in type 2 diabetes with Mytonomy’s state of the art patient experience cloud and modern learning science to help deliver better outcomes, higher levels of engagement and improved patient experience.
The two companies also collaborated with The Naomi Berrie Diabetes Center at Columbia University Medical Center, MedStar Diabetes Institute, and Duke Health’s Diabetes Program to gather a world class brain trust with deep clinical experience. These three preeminent diabetes education programs, plus Mytonomy and Sanofi focused on understanding the educational gaps in longitudinal activation of three of the fastest growing patient populations with type 2 diabetes who are new to insulin use – African American / Black, South Asian, and Hispanic / Latino patients. A new kind of patient education was created based on primary patient interviews and combined clinical experience.
Mytonomy’s Patient Experience Cloud is being used to deliver this unique content in a three site IRB (Institutional Review Board) approved clinical research study. To date, patient usage of the content delivered through Mytonomy’s Patient Experience Cloud software platform are extraordinarily high across all demographics, a range of literacy levels, ethnicities, races and age. The study is due to be completed by Q4 2017 with results that will be presented by the three participating healthcare system sites.
“This endeavor represents Sanofi’s commitment to developing solutions that fit into patients’ lives to help them better manage their medical conditions. Working with Mytonomy’s data platform holds tremendous promise for our ability to understand and address the needs of all people living with diabetes including those most at risk in the U.S.: African Americans, Hispanics and South Asians. This is part of our enhanced focus on leveraging the power of digital technology for analysis and intervention design,” said Anne Beal, M.D., MPH, SVP and Global Head of Patient Solutions, Sanofi.
“Collaborating with Sanofi and three world class institutions -- leaders in the fight to treat diabetes, gave us a chance to understand the real-world challenges that patients living with type 2 diabetes face in self-management and to deliver real value to these patients as evidenced by their usage and feedback,” said Anjali Kataria, CEO of Mytonomy. “This is just the beginning of our work with patients who have type 2 diabetes and are using insulin, and we will be sharing the results of the full program once the study is complete.”
About Diabetes
The International Diabetes Federation (IDF) estimates that 415 million people have diabetes today – a figure that IDF estimates could rise to 642 million by 2040.
Complications from poorly managed diabetes include cardiovascular disease, kidney disease, nerve damage and blindness. Diabetes and its complications account for 12% of global health expenditure ($673 billion US dollars).1
About Mytonomy
Mytonomy, Inc., based in Bethesda, MD, is the leader in Patient Experience Cloud Software for hospitals and providers. Mytonomy's solutions enable hospitals to drive high levels of patient satisfaction and improved patient outcomes through a state-of-the-art patient education, engagement and experience software platform. Mytonomy’s founders are former execs from Google, Oracle, and the FDA. The company is headquartered in Bethesda, MD and found online at http://www.mytonomy.com and @mytonomy.
Vinay Bhargava, Mytonomy, Inc, http://www.mytonomy.com, +1 650-906-8557, [email protected]
Share this article